JP2007501800A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007501800A5 JP2007501800A5 JP2006522776A JP2006522776A JP2007501800A5 JP 2007501800 A5 JP2007501800 A5 JP 2007501800A5 JP 2006522776 A JP2006522776 A JP 2006522776A JP 2006522776 A JP2006522776 A JP 2006522776A JP 2007501800 A5 JP2007501800 A5 JP 2007501800A5
- Authority
- JP
- Japan
- Prior art keywords
- carbon atoms
- alkyl
- group
- lower alkyl
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49313803P | 2003-08-07 | 2003-08-07 | |
| US53373403P | 2003-12-31 | 2003-12-31 | |
| PCT/US2004/025564 WO2005013949A2 (en) | 2003-08-07 | 2004-08-06 | Method for treating cachexia with retinoid ligands |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007501800A JP2007501800A (ja) | 2007-02-01 |
| JP2007501800A5 true JP2007501800A5 (enExample) | 2007-09-20 |
Family
ID=34138739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006522776A Pending JP2007501800A (ja) | 2003-08-07 | 2004-08-06 | レチノイドリガンドを用いて悪液質を処置するための方法 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1653939A2 (enExample) |
| JP (1) | JP2007501800A (enExample) |
| AU (1) | AU2004263156B2 (enExample) |
| CA (1) | CA2535260A1 (enExample) |
| WO (1) | WO2005013949A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1937244T3 (en) | 2005-09-30 | 2018-10-29 | Io Therapeutics Llc | : CANCER TREATMENT WITH SPECIFIC RXR AGONISTS |
| EP2056804B1 (en) * | 2006-08-16 | 2013-05-22 | Action Medicines, S.L. | Use of 2,5-dihydroxybenzene derivatives for the treatment of ocular diseases |
| US20120115912A1 (en) * | 2009-07-10 | 2012-05-10 | Landreth Gary E | Rxr agonist compounds and methods |
| EP2556827A1 (en) * | 2011-08-11 | 2013-02-13 | Acadia Pharmaceuticals Inc. | Treatment of neurodegenerative diseases |
| WO2013040227A2 (en) | 2011-09-15 | 2013-03-21 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University | Therapeutic compounds |
| US10653650B2 (en) | 2011-12-13 | 2020-05-19 | Io Therapeutics, Inc. | Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists |
| CN104114171A (zh) | 2011-12-13 | 2014-10-22 | Io治疗公司 | 使用rxr激动剂的自身免疫紊乱的治疗 |
| RU2720237C2 (ru) | 2013-11-18 | 2020-04-28 | Форма Терапеутикс, Инк. | Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет |
| DK3071203T3 (da) | 2013-11-18 | 2021-03-15 | Forma Therapeutics Inc | Tetrahydroquinolinsammensætninger som bet-bromdomæne-inhibitorer |
| EP3426302B1 (en) | 2016-03-10 | 2022-12-14 | IO Therapeutics, Inc. | Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones |
| DK3426303T3 (da) * | 2016-03-10 | 2022-09-19 | Io Therapeutics Inc | Behandling af muskellidelser med kombinationer af rxr-agonister og thyroideahormoner |
| US10238655B2 (en) | 2017-01-23 | 2019-03-26 | Arizona Board Of Regents On Behalf Of Arizona State University | Dihydroindene and tetrahydronaphthalene compounds |
| US10231947B2 (en) | 2017-01-23 | 2019-03-19 | Arizona Board Of Regents On Behalf Of Arizona State University | Isochroman compounds and methods of use thereof |
| US10238626B2 (en) | 2017-01-23 | 2019-03-26 | Arizona Board Of Regents On Behalf Of Arizona State University | Therapeutic compounds |
| EP3684348A4 (en) | 2017-09-20 | 2021-08-18 | IO Therapeutics, Inc. | TREATMENT OF DISEASE WITH SELECTIVE RXR AGONIST ESTERS |
| US10966950B2 (en) | 2019-06-11 | 2021-04-06 | Io Therapeutics, Inc. | Use of an RXR agonist in treating HER2+ cancers |
| JP2024543621A (ja) | 2021-12-07 | 2024-11-21 | アイオー セラピューティクス インコーポレイテッド | Ｈｅｒ２＋がんの治療におけるｒｘｒアゴニストおよびタキサンの使用 |
| WO2023108015A1 (en) | 2021-12-07 | 2023-06-15 | Io Therapeutics, Inc. | Use of an rxr agonist in treating drug resistant her2+ cancers |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6320074B1 (en) * | 1992-04-22 | 2001-11-20 | Ligand Pharmaceuticals Incorporated | Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors |
| MX9700778A (es) * | 1994-08-10 | 1997-05-31 | Hoffmann La Roche | Ligandos del receptor x del acido retinoico. |
| IL116259A (en) * | 1994-12-19 | 2000-07-16 | American Cyanamid Co | Analogs of 9-cis retinoic acid and their use |
| US5675033A (en) * | 1995-06-06 | 1997-10-07 | Allergan | 2,4-pentadienoic acid derivatives having retinoid-like biological activity |
| US5917082A (en) * | 1995-06-06 | 1999-06-29 | Allergan Sales, Inc. | 2,4-pentadienoic acid derivatives having retinoid-like biological activity |
-
2004
- 2004-08-06 EP EP04780406A patent/EP1653939A2/en not_active Withdrawn
- 2004-08-06 JP JP2006522776A patent/JP2007501800A/ja active Pending
- 2004-08-06 WO PCT/US2004/025564 patent/WO2005013949A2/en not_active Ceased
- 2004-08-06 CA CA002535260A patent/CA2535260A1/en not_active Abandoned
- 2004-08-06 AU AU2004263156A patent/AU2004263156B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007501800A5 (enExample) | ||
| JP2004516314A5 (enExample) | ||
| US9511060B2 (en) | Non-flushing niacin analogues, and methods of use thereof | |
| JP2009530398A5 (enExample) | ||
| CN113365998A (zh) | 用于parp抑制剂的吲哚并七元酰肟类似物 | |
| JP2004528307A5 (enExample) | ||
| JP2009539828A5 (enExample) | ||
| JP2013544887A5 (enExample) | ||
| JP2004526745A5 (enExample) | ||
| JP2004524312A5 (enExample) | ||
| JP2009114217A5 (enExample) | ||
| JP2010513224A5 (enExample) | ||
| JP2018135343A5 (enExample) | ||
| JP2012505836A5 (enExample) | ||
| JPWO2020123827A5 (enExample) | ||
| JP2004517099A5 (enExample) | ||
| JP2009507896A5 (enExample) | ||
| JP2009504748A5 (enExample) | ||
| JP2000026416A5 (enExample) | ||
| JP2008539268A5 (enExample) | ||
| JP2006524252A5 (enExample) | ||
| JPH10287651A5 (enExample) | ||
| JP2007517037A5 (enExample) | ||
| WO2005013949A2 (en) | Method for treating cachexia with retinoid ligands | |
| RU2004117595A (ru) | Производные пиридина в качестве лигандов рецептора nmda |